D. Bron MD, PhD, S. Wittnebel MD, PhD, V. Thibaud MD
After a successful first edition in Lisbon, a second edition of this scientific working group meeting was held in Warsaw in October 2018. The objective was to organise roundtables with scientists, clinicians, onconurses and patient’s organisations to improve the management of older patients with haematological disorders. Several unsolved issues were debated as outlined below.
S. Dubruille PhD, V. Thibaud MD, T. Pepersack MD, PhD, D. Bron MD, PhD
Frailty assessment in older patients with malignant hemopathies is very useful in order to improve care and treatment options. However, some lacks of data exist regarding the unsuspected frail population in presumed ‘clinically fit’ patients who should not benefit from chemotherapy. In this article, we review current data regarding prognostic factors and frailty scoring in older patients with malignant hemopathies. Prospective trials are needed to build a new frailty scoring to assess the unsuspected frail population in ‘clinically fit’ patients including specifically assessment of cognitive impairment.